{
    "id": "dbpedia_1140_0",
    "rank": 7,
    "data": {
        "url": "https://patents.google.com/patent/US10441586B2/en",
        "read_more_link": "",
        "language": "en",
        "title": "US10441586B2 - CRMP2 SUMOylation inhibitors and uses thereof - Google Patents",
        "top_image": "https://patentimages.storage.googleapis.com/ec/dd/cd/0d2ebc17ab73eb/US10441586-20191015-C00001.png",
        "meta_img": "",
        "images": [
            "https://patentimages.storage.googleapis.com/d8/b6/c1/98cbf13f3222ad/US10441586-20191015-D00001.png",
            "https://patentimages.storage.googleapis.com/f5/b3/00/31075ca8d75e2d/US10441586-20191015-D00002.png",
            "https://patentimages.storage.googleapis.com/b0/ed/7c/2dafd6b0ec6df6/US10441586-20191015-D00003.png",
            "https://patentimages.storage.googleapis.com/7c/ce/d0/bf247cb78e1e19/US10441586-20191015-D00004.png",
            "https://patentimages.storage.googleapis.com/c7/a7/49/4cc951e7ecd36e/US10441586-20191015-D00005.png",
            "https://patentimages.storage.googleapis.com/31/05/0f/f04f6b0bbbd2e7/US10441586-20191015-D00006.png",
            "https://patentimages.storage.googleapis.com/3d/e9/bb/48473921b2abac/US10441586-20191015-D00007.png",
            "https://patentimages.storage.googleapis.com/b2/76/d9/ba9d8cc2c1a0eb/US10441586-20191015-D00008.png",
            "https://patentimages.storage.googleapis.com/ec/dd/cd/0d2ebc17ab73eb/US10441586-20191015-C00001.png",
            "https://patentimages.storage.googleapis.com/0e/07/03/a43dd00cbc239c/US10441586-20191015-C00002.png",
            "https://patentimages.storage.googleapis.com/bb/c9/ee/ac5d8b73385d4a/US10441586-20191015-C00003.png",
            "https://patentimages.storage.googleapis.com/30/ae/15/eaf0d41a1dc573/US10441586-20191015-C00004.png",
            "https://patentimages.storage.googleapis.com/b6/48/84/b564017965b557/US10441586-20191015-C00005.png",
            "https://patentimages.storage.googleapis.com/51/44/57/d8c170c52f9683/US10441586-20191015-C00006.png",
            "https://patentimages.storage.googleapis.com/e1/3b/c9/256f25e606b599/US10441586-20191015-C00007.png",
            "https://patentimages.storage.googleapis.com/30/27/6c/7aa31abce1e87f/US10441586-20191015-C00008.png",
            "https://patentimages.storage.googleapis.com/b7/d6/41/a7fcb348fd6dc0/US10441586-20191015-C00009.png",
            "https://patentimages.storage.googleapis.com/4f/28/5c/489ed5be2df153/US10441586-20191015-C00010.png",
            "https://patentimages.storage.googleapis.com/5a/0c/44/8a8d416cec8430/US10441586-20191015-C00011.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2015-10-07T00:00:00",
        "summary": "",
        "meta_description": "The present invention provides compounds that can modulate the amount of Nav 1.7 protein, a key protein in pain signaling, that is present in the cellular surface and methods for using such compounds. In particular, compounds of the invention modulate the amount of Nav 1.7 protein on the cellular surface by modulating SUMOylation of CRMP2. Thus, compounds of the invention can be used to treat various clinical conditions associated with the presence and/or activation of Nav 1.7 protein on the cellular surface and/or SUMOylation of CRMP2.",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/US10441586B2/en",
        "text": "CRMP2 SUMOylation inhibitors and uses thereof Download PDF\n\nInfo\n\nPublication number\n\nUS10441586B2\n\nUS10441586B2 US15/766,299 US201615766299A US10441586B2 US 10441586 B2 US10441586 B2 US 10441586B2 US 201615766299 A US201615766299 A US 201615766299A US 10441586 B2 US10441586 B2 US 10441586B2\n\nAuthority\n\nUS\n\nUnited States\n\nPrior art keywords\n\ncompounds\n\ncompound\n\nacid\n\nmethoxy\n\npain\n\nPrior art date\n\n2015-10-07\n\nLegal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)\n\nActive\n\nApplication number\n\nUS15/766,299\n\nOther versions\n\nUS20180289700A1 (en\n\nInventor\n\nMay KHANNA\n\nRajesh Khanna\n\nVijay Gokhale\n\nReena Chawla\n\nCurrent Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)\n\nUniversity of Arizona\n\nOriginal Assignee\n\nUniversity of Arizona\n\nPriority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)\n\n2015-10-07\n\nFiling date\n\n2016-10-07\n\nPublication date\n\n2019-10-15\n\n2016-10-07 Application filed by University of Arizona filed Critical University of Arizona\n\n2016-10-07 Priority to US15/766,299 priority Critical patent/US10441586B2/en\n\n2018-10-11 Publication of US20180289700A1 publication Critical patent/US20180289700A1/en\n\n2019-08-29 Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA reassignment ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHANNA, May, KHANNA, RAJESH, CHAWLA, Reena, GOKHALE, VIJAY\n\n2019-10-15 Application granted granted Critical\n\n2019-10-15 Publication of US10441586B2 publication Critical patent/US10441586B2/en\n\nStatus Active legal-status Critical Current\n\n2036-10-07 Anticipated expiration legal-status Critical\n\nLinks\n\nUSPTO\n\nUSPTO PatentCenter\n\nUSPTO Assignment\n\nEspacenet\n\nGlobal Dossier\n\nDiscuss\n\n102100024426 Dihydropyrimidinase-related protein 2 Human genes 0.000 title abstract description 26\n\n101001053503 Homo sapiens Dihydropyrimidinase-related protein 2 Proteins 0.000 title abstract description 26\n\n230000010741 sumoylation Effects 0.000 title abstract description 18\n\n239000003112 inhibitor Substances 0.000 title description 7\n\n150000001875 compounds Chemical class 0.000 claims abstract description 132\n\n229910052739 hydrogen Inorganic materials 0.000 claims description 11\n\n239000001257 hydrogen Substances 0.000 claims description 11\n\n229910052760 oxygen Inorganic materials 0.000 claims description 8\n\n125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6\n\n125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1\n\n238000000034 method Methods 0.000 abstract description 30\n\n230000001413 cellular effect Effects 0.000 abstract description 19\n\n102000004169 proteins and genes Human genes 0.000 abstract description 13\n\n108090000623 proteins and genes Proteins 0.000 abstract description 13\n\n230000004913 activation Effects 0.000 abstract description 10\n\n230000008050 pain signaling Effects 0.000 abstract 1\n\n-1 benzo[d][1,3]dioxolyl Chemical group 0.000 description 48\n\nYMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39\n\n239000000203 mixture Substances 0.000 description 35\n\n208000002193 Pain Diseases 0.000 description 33\n\n210000004027 cell Anatomy 0.000 description 32\n\n239000007787 solid Substances 0.000 description 31\n\nIAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30\n\nIJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26\n\nIAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26\n\n239000000243 solution Substances 0.000 description 26\n\n230000015572 biosynthetic process Effects 0.000 description 25\n\n230000036407 pain Effects 0.000 description 25\n\n238000003786 synthesis reaction Methods 0.000 description 25\n\n101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 22\n\n238000005160 1H NMR spectroscopy Methods 0.000 description 20\n\n102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 20\n\n238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 18\n\nHEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 17\n\nZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17\n\n239000000047 product Substances 0.000 description 17\n\n241000700159 Rattus Species 0.000 description 16\n\n150000003839 salts Chemical class 0.000 description 16\n\n125000001424 substituent group Chemical group 0.000 description 16\n\nOKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15\n\n239000000370 acceptor Substances 0.000 description 15\n\n201000010099 disease Diseases 0.000 description 15\n\n208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15\n\n229910052757 nitrogen Inorganic materials 0.000 description 15\n\n210000003594 spinal ganglia Anatomy 0.000 description 15\n\n238000002360 preparation method Methods 0.000 description 14\n\n239000000843 powder Substances 0.000 description 13\n\n238000003756 stirring Methods 0.000 description 12\n\nFYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12\n\nXLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12\n\n239000004480 active ingredient Substances 0.000 description 11\n\n239000008194 pharmaceutical composition Substances 0.000 description 11\n\nFAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10\n\n125000000217 alkyl group Chemical group 0.000 description 10\n\n238000006243 chemical reaction Methods 0.000 description 10\n\n230000002779 inactivation Effects 0.000 description 10\n\n238000001890 transfection Methods 0.000 description 10\n\nLFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9\n\nXEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9\n\n239000011324 bead Substances 0.000 description 9\n\n238000002474 experimental method Methods 0.000 description 9\n\n125000000623 heterocyclic group Chemical group 0.000 description 9\n\n230000002401 inhibitory effect Effects 0.000 description 9\n\n210000002569 neuron Anatomy 0.000 description 9\n\n239000003826 tablet Substances 0.000 description 9\n\n238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8\n\nMWAYRGBWOVHDDZ-UHFFFAOYSA-N Ethyl vanillate Chemical compound CCOC(=O)C1=CC=C(O)C(OC)=C1 MWAYRGBWOVHDDZ-UHFFFAOYSA-N 0.000 description 8\n\nTWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8\n\n239000002775 capsule Substances 0.000 description 8\n\n239000002552 dosage form Substances 0.000 description 8\n\n238000009472 formulation Methods 0.000 description 8\n\n125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8\n\n239000000651 prodrug Substances 0.000 description 8\n\n229940002612 prodrug Drugs 0.000 description 8\n\n235000018102 proteins Nutrition 0.000 description 8\n\nWEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7\n\n108091006146 Channels Proteins 0.000 description 7\n\n208000000094 Chronic Pain Diseases 0.000 description 7\n\nZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7\n\n125000006239 protecting group Chemical group 0.000 description 7\n\n239000011541 reaction mixture Substances 0.000 description 7\n\n238000012360 testing method Methods 0.000 description 7\n\nJKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6\n\nCGLIQMSZLNFKAV-UHFFFAOYSA-N 3-methoxy-4-[[3-(trifluoromethyl)phenyl]methoxy]benzoic acid Chemical compound COC=1C=C(C(=O)O)C=CC=1OCC1=CC(=CC=C1)C(F)(F)F CGLIQMSZLNFKAV-UHFFFAOYSA-N 0.000 description 6\n\nUOEWNVLNJWMUAY-UHFFFAOYSA-N COC=1C=C(C(=O)OCC)C=CC=1OCC1=CC(=CC=C1)C(F)(F)F Chemical compound COC=1C=C(C(=O)OCC)C=CC=1OCC1=CC(=CC=C1)C(F)(F)F UOEWNVLNJWMUAY-UHFFFAOYSA-N 0.000 description 6\n\n239000007995 HEPES buffer Substances 0.000 description 6\n\nDGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6\n\n208000028389 Nerve injury Diseases 0.000 description 6\n\nDNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6\n\nYXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6\n\n238000004458 analytical method Methods 0.000 description 6\n\n239000003085 diluting agent Substances 0.000 description 6\n\n230000006870 function Effects 0.000 description 6\n\n125000001188 haloalkyl group Chemical group 0.000 description 6\n\n230000008764 nerve damage Effects 0.000 description 6\n\n239000000546 pharmaceutical excipient Substances 0.000 description 6\n\nBWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6\n\nNLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6\n\n239000002244 precipitate Substances 0.000 description 6\n\n238000010992 reflux Methods 0.000 description 6\n\n230000004044 response Effects 0.000 description 6\n\n239000011734 sodium Substances 0.000 description 6\n\n229910052708 sodium Inorganic materials 0.000 description 6\n\n239000002904 solvent Substances 0.000 description 6\n\n238000011282 treatment Methods 0.000 description 6\n\nMOZNZNKHRXRLLF-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1 MOZNZNKHRXRLLF-UHFFFAOYSA-N 0.000 description 5\n\nHRWITLKRRXAYJL-UHFFFAOYSA-N COC=1C=C(C(=O)Cl)C=CC=1OCC1=CC(=CC=C1)C(F)(F)F Chemical compound COC=1C=C(C(=O)Cl)C=CC=1OCC1=CC(=CC=C1)C(F)(F)F HRWITLKRRXAYJL-UHFFFAOYSA-N 0.000 description 5\n\n102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 description 5\n\n108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 description 5\n\n239000002585 base Substances 0.000 description 5\n\n125000004432 carbon atom Chemical group C* 0.000 description 5\n\n239000000969 carrier Substances 0.000 description 5\n\n239000003795 chemical substances by application Substances 0.000 description 5\n\n229940079593 drug Drugs 0.000 description 5\n\n239000003814 drug Substances 0.000 description 5\n\n239000003937 drug carrier Substances 0.000 description 5\n\n230000000694 effects Effects 0.000 description 5\n\n239000000839 emulsion Substances 0.000 description 5\n\n125000004404 heteroalkyl group Chemical group 0.000 description 5\n\n239000007788 liquid Substances 0.000 description 5\n\n230000004048 modification Effects 0.000 description 5\n\n238000012986 modification Methods 0.000 description 5\n\n208000004296 neuralgia Diseases 0.000 description 5\n\n208000021722 neuropathic pain Diseases 0.000 description 5\n\n239000013612 plasmid Substances 0.000 description 5\n\n239000011780 sodium chloride Substances 0.000 description 5\n\n239000000725 suspension Substances 0.000 description 5\n\nLMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4\n\n239000006144 Dulbeccoâs modiï¬ed Eagle's medium Substances 0.000 description 4\n\nVEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4\n\n208000004454 Hyperalgesia Diseases 0.000 description 4\n\n238000005481 NMR spectroscopy Methods 0.000 description 4\n\n239000007832 Na2SO4 Substances 0.000 description 4\n\nPMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4\n\n125000003545 alkoxy group Chemical group 0.000 description 4\n\n125000002947 alkylene group Chemical group 0.000 description 4\n\n125000003118 aryl group Chemical group 0.000 description 4\n\nQVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4\n\nYKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 4\n\n235000019439 ethyl acetate Nutrition 0.000 description 4\n\n210000002683 foot Anatomy 0.000 description 4\n\n125000005843 halogen group Chemical group 0.000 description 4\n\n125000005842 heteroatom Chemical group 0.000 description 4\n\n238000004128 high performance liquid chromatography Methods 0.000 description 4\n\n150000002430 hydrocarbons Chemical group 0.000 description 4\n\n238000000126 in silico method Methods 0.000 description 4\n\n239000010410 layer Substances 0.000 description 4\n\n125000005647 linker group Chemical group 0.000 description 4\n\n239000007937 lozenge Substances 0.000 description 4\n\n229910001629 magnesium chloride Inorganic materials 0.000 description 4\n\n210000003205 muscle Anatomy 0.000 description 4\n\n239000012044 organic layer Substances 0.000 description 4\n\n239000001301 oxygen Substances 0.000 description 4\n\n230000008569 process Effects 0.000 description 4\n\n125000006413 ring segment Chemical group 0.000 description 4\n\n229920006395 saturated elastomer Polymers 0.000 description 4\n\n210000003491 skin Anatomy 0.000 description 4\n\n229910052938 sodium sulfate Inorganic materials 0.000 description 4\n\n239000007921 spray Substances 0.000 description 4\n\n239000003381 stabilizer Substances 0.000 description 4\n\n239000000375 suspending agent Substances 0.000 description 4\n\n238000013268 sustained release Methods 0.000 description 4\n\n208000024891 symptom Diseases 0.000 description 4\n\n239000002562 thickening agent Substances 0.000 description 4\n\n238000004809 thin layer chromatography Methods 0.000 description 4\n\nGBMPUGYTXRHCKB-UHFFFAOYSA-N 3-fluoro-4-(2-morpholin-4-ylethoxy)benzoic acid Chemical compound FC=1C=C(C(=O)O)C=CC=1OCCN1CCOCC1 GBMPUGYTXRHCKB-UHFFFAOYSA-N 0.000 description 3\n\nQTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3\n\nFOALRRUAVKVVHJ-UHFFFAOYSA-N C(#N)C1=CC=C(COC2=C(C=C(C(=O)Cl)C=C2)OC)C=C1 Chemical compound C(#N)C1=CC=C(COC2=C(C=C(C(=O)Cl)C=C2)OC)C=C1 FOALRRUAVKVVHJ-UHFFFAOYSA-N 0.000 description 3\n\nBDUDOCFUCWZQSP-UHFFFAOYSA-N C(#N)C1=CC=C(COC2=C(C=C(C(=O)NC3=CC=C(C=C3)N3CCN(CC3)C)C=C2)OC)C=C1 Chemical compound C(#N)C1=CC=C(COC2=C(C=C(C(=O)NC3=CC=C(C=C3)N3CCN(CC3)C)C=C2)OC)C=C1 BDUDOCFUCWZQSP-UHFFFAOYSA-N 0.000 description 3\n\n0 COC(C*)CCNc(cc1)ccc1NC(c(cc1)cc(OC)c1OCc(cc1)ccc1C#N)=O Chemical compound COC(C*)CCNc(cc1)ccc1NC(c(cc1)cc(OC)c1OCc(cc1)ccc1C#N)=O 0.000 description 3\n\nQEBXRHWELZTZOA-UHFFFAOYSA-N COC=1C=C(C(=O)Cl)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F Chemical compound COC=1C=C(C(=O)Cl)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F QEBXRHWELZTZOA-UHFFFAOYSA-N 0.000 description 3\n\nUXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3\n\nCURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3\n\nOKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3\n\nJPLCGCQMSQUBIV-UHFFFAOYSA-N FC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1O Chemical compound FC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1O JPLCGCQMSQUBIV-UHFFFAOYSA-N 0.000 description 3\n\n239000001828 Gelatine Substances 0.000 description 3\n\nWQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3\n\n239000007821 HATU Substances 0.000 description 3\n\n206010020751 Hypersensitivity Diseases 0.000 description 3\n\n235000010643 Leucaena leucocephala Nutrition 0.000 description 3\n\n240000007472 Leucaena leucocephala Species 0.000 description 3\n\nOFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3\n\n241000124008 Mammalia Species 0.000 description 3\n\nJGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3\n\n102000051619 SUMO-1 Human genes 0.000 description 3\n\n108700038981 SUMO-1 Proteins 0.000 description 3\n\nHEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3\n\nQAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3\n\n208000027418 Wounds and injury Diseases 0.000 description 3\n\n208000005298 acute pain Diseases 0.000 description 3\n\n208000026935 allergic disease Diseases 0.000 description 3\n\n238000012440 amplified luminescent proximity homogeneous assay Methods 0.000 description 3\n\n238000003556 assay Methods 0.000 description 3\n\n230000008901 benefit Effects 0.000 description 3\n\nWPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3\n\n239000001110 calcium chloride Substances 0.000 description 3\n\n229910001628 calcium chloride Inorganic materials 0.000 description 3\n\nKRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3\n\n239000003086 colorant Substances 0.000 description 3\n\n239000006071 cream Substances 0.000 description 3\n\n238000011161 development Methods 0.000 description 3\n\n239000002270 dispersing agent Substances 0.000 description 3\n\n239000000796 flavoring agent Substances 0.000 description 3\n\n125000001153 fluoro group Chemical group F* 0.000 description 3\n\n229920000159 gelatin Polymers 0.000 description 3\n\n235000019322 gelatine Nutrition 0.000 description 3\n\n125000002887 hydroxy group Chemical group [H]O* 0.000 description 3\n\n230000009610 hypersensitivity Effects 0.000 description 3\n\n238000001727 in vivo Methods 0.000 description 3\n\n239000004615 ingredient Substances 0.000 description 3\n\n238000002347 injection Methods 0.000 description 3\n\n239000007924 injection Substances 0.000 description 3\n\n208000014674 injury Diseases 0.000 description 3\n\n150000002611 lead compounds Chemical class 0.000 description 3\n\n230000028161 membrane depolarization Effects 0.000 description 3\n\n238000003032 molecular docking Methods 0.000 description 3\n\n230000035772 mutation Effects 0.000 description 3\n\n230000001537 neural effect Effects 0.000 description 3\n\n229910000027 potassium carbonate Inorganic materials 0.000 description 3\n\n230000036278 prepulse Effects 0.000 description 3\n\n238000012216 screening Methods 0.000 description 3\n\n239000000126 substance Substances 0.000 description 3\n\n229910052717 sulfur Inorganic materials 0.000 description 3\n\n239000000829 suppository Substances 0.000 description 3\n\n239000012730 sustained-release form Substances 0.000 description 3\n\n230000001225 therapeutic effect Effects 0.000 description 3\n\n238000002560 therapeutic procedure Methods 0.000 description 3\n\n239000003981 vehicle Substances 0.000 description 3\n\nZRSGZIMDIHBXIN-UHFFFAOYSA-N 1,3-benzodioxole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2OCOC2=C1 ZRSGZIMDIHBXIN-UHFFFAOYSA-N 0.000 description 2\n\nAXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2\n\nIIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\\C=C/C\\C=C/C\\C=C/C\\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2\n\nWEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2\n\nHZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2\n\nVEXBAJGCHDQYMR-UHFFFAOYSA-N 3-fluoro-N-[4-(4-methylpiperazin-1-yl)phenyl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound CN1CCN(CC1)c1ccc(NC(=O)c2ccc(OCCN3CCOCC3)c(F)c2)cc1 VEXBAJGCHDQYMR-UHFFFAOYSA-N 0.000 description 2\n\nXMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2\n\nYUMYCPNZTXPUTQ-UHFFFAOYSA-N 4-(2-chloroethyl)piperidin-1-ium;chloride Chemical compound Cl.ClCCC1CCNCC1 YUMYCPNZTXPUTQ-UHFFFAOYSA-N 0.000 description 2\n\nKDSGFDGTUWELFP-UHFFFAOYSA-N 4-(4-methoxypiperidin-1-yl)aniline Chemical compound C1CC(OC)CCN1C1=CC=C(N)C=C1 KDSGFDGTUWELFP-UHFFFAOYSA-N 0.000 description 2\n\nNCKZXQFJRWRVJY-UHFFFAOYSA-N 4-[(4-cyanophenyl)methoxy]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1OCC1=CC=C(C#N)C=C1 NCKZXQFJRWRVJY-UHFFFAOYSA-N 0.000 description 2\n\n206010001497 Agitation Diseases 0.000 description 2\n\n208000024827 Alzheimer disease Diseases 0.000 description 2\n\n206010002091 Anaesthesia Diseases 0.000 description 2\n\n241000416162 Astragalus gummifer Species 0.000 description 2\n\nHGAYUKTYIDUUMV-UHFFFAOYSA-N C(#N)C1=CC=C(COC2=C(C=C(C(=O)NC3=CC=C(C=C3)N3CCC(CC3)OC)C=C2)OC)C=C1 Chemical compound C(#N)C1=CC=C(COC2=C(C=C(C(=O)NC3=CC=C(C=C3)N3CCC(CC3)OC)C=C2)OC)C=C1 HGAYUKTYIDUUMV-UHFFFAOYSA-N 0.000 description 2\n\nXPHCBTZKROVBRH-UHFFFAOYSA-N C(#N)C1=CC=C(COC2=C(C=C(C(=O)OCC)C=C2)OC)C=C1 Chemical compound C(#N)C1=CC=C(COC2=C(C=C(C(=O)OCC)C=C2)OC)C=C1 XPHCBTZKROVBRH-UHFFFAOYSA-N 0.000 description 2\n\nYICAMJWHIUMFDI-UHFFFAOYSA-N CC(=O)NC1=CC=C(C)C=C1 Chemical compound CC(=O)NC1=CC=C(C)C=C1 YICAMJWHIUMFDI-UHFFFAOYSA-N 0.000 description 2\n\nKFILAYHYKHWEDW-UHFFFAOYSA-N COC1CCN(CC1)C1=CC=C(NC(=O)C2=CC3=C(OCO3)C=C2)C=C1 Chemical compound COC1CCN(CC1)C1=CC=C(NC(=O)C2=CC3=C(OCO3)C=C2)C=C1 KFILAYHYKHWEDW-UHFFFAOYSA-N 0.000 description 2\n\nWWWAKYSZDHGRGX-UHFFFAOYSA-N COC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1OCC1=CC(=CC=C1)C(F)(F)F Chemical compound COC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1OCC1=CC(=CC=C1)C(F)(F)F WWWAKYSZDHGRGX-UHFFFAOYSA-N 0.000 description 2\n\nKMSHSVVCBPUPNH-UHFFFAOYSA-N COC=1C=C(C(=O)O)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F Chemical compound COC=1C=C(C(=O)O)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F KMSHSVVCBPUPNH-UHFFFAOYSA-N 0.000 description 2\n\nFPOMLGOQLBTENO-UHFFFAOYSA-N COC=1C=C(C(=O)OCC)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F Chemical compound COC=1C=C(C(=O)OCC)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F FPOMLGOQLBTENO-UHFFFAOYSA-N 0.000 description 2\n\n101100539164 Caenorhabditis elegans ubc-9 gene Proteins 0.000 description 2\n\nRGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2\n\nMYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical class O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2\n\nLILLXEHOZUSDAB-UHFFFAOYSA-N FC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1OCCN1CCCCC1 Chemical compound FC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1OCCN1CCCCC1 LILLXEHOZUSDAB-UHFFFAOYSA-N 0.000 description 2\n\nVZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\\C=C\\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2\n\nUGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2\n\nPEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2\n\nAEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2\n\n101000640020 Homo sapiens Sodium channel protein type 11 subunit alpha Proteins 0.000 description 2\n\n208000035154 Hyperesthesia Diseases 0.000 description 2\n\nGUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2\n\n239000012097 Lipofectamine 2000 Substances 0.000 description 2\n\nCSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2\n\n241001465754 Metazoa Species 0.000 description 2\n\nAFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2\n\n208000012902 Nervous system disease Diseases 0.000 description 2\n\n208000025966 Neurological disease Diseases 0.000 description 2\n\n208000018737 Parkinson disease Diseases 0.000 description 2\n\n229930182555 Penicillin Natural products 0.000 description 2\n\nJGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2\n\nNBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2\n\n239000002202 Polyethylene glycol Substances 0.000 description 2\n\n229920002873 Polyethylenimine Polymers 0.000 description 2\n\n102000001708 Protein Isoforms Human genes 0.000 description 2\n\n108010029485 Protein Isoforms Proteins 0.000 description 2\n\n208000003251 Pruritus Diseases 0.000 description 2\n\nJUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2\n\nLCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2\n\nVYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2\n\n108020004459 Small interfering RNA Proteins 0.000 description 2\n\nUIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2\n\n102100033974 Sodium channel protein type 11 subunit alpha Human genes 0.000 description 2\n\n229920002472 Starch Polymers 0.000 description 2\n\n229930006000 Sucrose Natural products 0.000 description 2\n\nCZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2\n\n229920001615 Tragacanth Polymers 0.000 description 2\n\n102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 2\n\nDPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2\n\n230000036982 action potential Effects 0.000 description 2\n\n239000002671 adjuvant Substances 0.000 description 2\n\n239000000443 aerosol Substances 0.000 description 2\n\n230000037005 anaesthesia Effects 0.000 description 2\n\n229940035676 analgesics Drugs 0.000 description 2\n\n239000000730 antalgic agent Substances 0.000 description 2\n\n239000007864 aqueous solution Substances 0.000 description 2\n\n239000007900 aqueous suspension Substances 0.000 description 2\n\n125000004104 aryloxy group Chemical group 0.000 description 2\n\n230000003542 behavioural effect Effects 0.000 description 2\n\n125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2\n\nAIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2\n\n229910002092 carbon dioxide Inorganic materials 0.000 description 2\n\n125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2\n\n239000001768 carboxy methyl cellulose Substances 0.000 description 2\n\n239000003153 chemical reaction reagent Substances 0.000 description 2\n\n238000003501 co-culture Methods 0.000 description 2\n\n229940110456 cocoa butter Drugs 0.000 description 2\n\n235000019868 cocoa butter Nutrition 0.000 description 2\n\n108010022822 collapsin response mediator protein-2 Proteins 0.000 description 2\n\n230000003750 conditioning effect Effects 0.000 description 2\n\n239000012043 crude product Substances 0.000 description 2\n\n238000012258 culturing Methods 0.000 description 2\n\n125000004122 cyclic group Chemical group 0.000 description 2\n\n230000001086 cytosolic effect Effects 0.000 description 2\n\n230000006735 deficit Effects 0.000 description 2\n\n230000001419 dependent effect Effects 0.000 description 2\n\nXBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2\n\n239000003995 emulsifying agent Substances 0.000 description 2\n\n201000011384 erythromelalgia Diseases 0.000 description 2\n\nRKOONLMCCXXOJC-UHFFFAOYSA-N ethyl 3-fluoro-4-(2-morpholin-4-ylethoxy)benzoate Chemical compound FC1=CC(C(=O)OCC)=CC=C1OCCN1CCOCC1 RKOONLMCCXXOJC-UHFFFAOYSA-N 0.000 description 2\n\nQEOZGTBBNDHZSK-UHFFFAOYSA-N ethyl 3-fluoro-4-hydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(F)=C1 QEOZGTBBNDHZSK-UHFFFAOYSA-N 0.000 description 2\n\nDEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2\n\n239000012091 fetal bovine serum Substances 0.000 description 2\n\n235000019634 flavors Nutrition 0.000 description 2\n\n239000000499 gel Substances 0.000 description 2\n\nBRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2\n\nRWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2\n\n125000004438 haloalkoxy group Chemical group 0.000 description 2\n\n230000036541 health Effects 0.000 description 2\n\n125000002883 imidazolyl group Chemical group 0.000 description 2\n\n238000011534 incubation Methods 0.000 description 2\n\n238000001802 infusion Methods 0.000 description 2\n\n230000005764 inhibitory process Effects 0.000 description 2\n\n239000000543 intermediate Substances 0.000 description 2\n\n230000003834 intracellular effect Effects 0.000 description 2\n\n238000007913 intrathecal administration Methods 0.000 description 2\n\nSUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2\n\nJVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2\n\n239000008101 lactose Substances 0.000 description 2\n\n239000000787 lecithin Substances 0.000 description 2\n\n235000010445 lecithin Nutrition 0.000 description 2\n\n229940067606 lecithin Drugs 0.000 description 2\n\n239000006210 lotion Substances 0.000 description 2\n\nHQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2\n\n239000000463 material Substances 0.000 description 2\n\n230000007246 mechanism Effects 0.000 description 2\n\n230000001404 mediated effect Effects 0.000 description 2\n\n238000002844 melting Methods 0.000 description 2\n\n230000008018 melting Effects 0.000 description 2\n\nDZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 2\n\n229920000609 methyl cellulose Polymers 0.000 description 2\n\n239000001923 methylcellulose Substances 0.000 description 2\n\n235000010981 methylcellulose Nutrition 0.000 description 2\n\nBQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2\n\nTXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2\n\nVLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2\n\nRMRZEGSVZVXWGV-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-benzodioxole-5-carboxamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(=O)C1=CC=C(OCO2)C2=C1 RMRZEGSVZVXWGV-UHFFFAOYSA-N 0.000 description 2\n\nFUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2\n\n210000003928 nasal cavity Anatomy 0.000 description 2\n\n125000004433 nitrogen atom Chemical group N* 0.000 description 2\n\n210000000929 nociceptor Anatomy 0.000 description 2\n\n239000003921 oil Substances 0.000 description 2\n\n235000019198 oils Nutrition 0.000 description 2\n\n239000002674 ointment Substances 0.000 description 2\n\n229940005483 opioid analgesics Drugs 0.000 description 2\n\n208000019865 paroxysmal extreme pain disease Diseases 0.000 description 2\n\n239000002245 particle Substances 0.000 description 2\n\n229940049954 penicillin Drugs 0.000 description 2\n\n125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2\n\n125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2\n\n229910052698 phosphorus Inorganic materials 0.000 description 2\n\n239000006187 pill Substances 0.000 description 2\n\n125000004193 piperazinyl group Chemical group 0.000 description 2\n\n229920001223 polyethylene glycol Polymers 0.000 description 2\n\n229920006316 polyvinylpyrrolidine Polymers 0.000 description 2\n\n239000003755 preservative agent Substances 0.000 description 2\n\n125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2\n\n208000017692 primary erythermalgia Diseases 0.000 description 2\n\n230000000069 prophylactic effect Effects 0.000 description 2\n\n125000005550 pyrazinylene group Chemical group 0.000 description 2\n\n125000005551 pyridylene group Chemical group 0.000 description 2\n\n230000002829 reductive effect Effects 0.000 description 2\n\n238000002390 rotary evaporation Methods 0.000 description 2\n\nYGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2\n\n210000003497 sciatic nerve Anatomy 0.000 description 2\n\n210000001044 sensory neuron Anatomy 0.000 description 2\n\n235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2\n\n229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2\n\n239000008107 starch Substances 0.000 description 2\n\n235000019698 starch Nutrition 0.000 description 2\n\n229960002385 streptomycin sulfate Drugs 0.000 description 2\n\n238000007920 subcutaneous administration Methods 0.000 description 2\n\n239000005720 sucrose Substances 0.000 description 2\n\nYMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 2\n\nCFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2\n\n229950010357 tetrodotoxin Drugs 0.000 description 2\n\nCFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2\n\n125000003396 thiol group Chemical group [H]S* 0.000 description 2\n\n238000011200 topical administration Methods 0.000 description 2\n\n239000000196 tragacanth Substances 0.000 description 2\n\n235000010487 tragacanth Nutrition 0.000 description 2\n\n229940116362 tragacanth Drugs 0.000 description 2\n\nVZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2\n\n238000010361 transduction Methods 0.000 description 2\n\n230000026683 transduction Effects 0.000 description 2\n\n125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2\n\n125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2\n\n238000001262 western blot Methods 0.000 description 2\n\nQBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1\n\nMIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1\n\nBJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1\n\nWBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\\C=C\\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1\n\nZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1\n\nDDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1\n\nMYYYZNVAUZVXBO-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CBr)=C1 MYYYZNVAUZVXBO-UHFFFAOYSA-N 0.000 description 1\n\nASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1\n\nAMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1\n\nHUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1\n\nUPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1\n\n125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1\n\nXLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1\n\nBMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1\n\nZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1\n\nIUSDEKNMCOUBEE-UHFFFAOYSA-N 3-fluoro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(F)=C1 IUSDEKNMCOUBEE-UHFFFAOYSA-N 0.000 description 1\n\nZSIFZEDSVXGFHP-UHFFFAOYSA-N 3-fluoro-4-hydroxybenzoyl chloride Chemical compound OC1=CC=C(C(Cl)=O)C=C1F ZSIFZEDSVXGFHP-UHFFFAOYSA-N 0.000 description 1\n\n125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1\n\nQCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1\n\nNUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1\n\nRJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1\n\nQTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1\n\n206010002653 Anosmia Diseases 0.000 description 1\n\n108090000145 Bacillolysin Proteins 0.000 description 1\n\n239000005711 Benzoic acid Substances 0.000 description 1\n\nBVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1\n\n108091003079 Bovine Serum Albumin Proteins 0.000 description 1\n\nVQANNLKYKCAVKE-UHFFFAOYSA-M CC(=O)N1CCN(C2=CC=C(NC(=O)C3=CC(CO)=CC=C3)C=C2)CC1.CC(C)OC1=CC=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=C1.CC1CCN(C2=CC=C(NC(=O)C3=CC=C(OCC[NH+]4CCCCC4)C(F)=C3)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC(CO)=C1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC(CO)=C1CO.O=C[O-].O=C[O-] Chemical compound CC(=O)N1CCN(C2=CC=C(NC(=O)C3=CC(CO)=CC=C3)C=C2)CC1.CC(C)OC1=CC=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=C1.CC1CCN(C2=CC=C(NC(=O)C3=CC=C(OCC[NH+]4CCCCC4)C(F)=C3)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC(CO)=C1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC(CO)=C1CO.O=C[O-].O=C[O-] VQANNLKYKCAVKE-UHFFFAOYSA-M 0.000 description 1\n\nCXBPKQWVXHXYQZ-UHFFFAOYSA-N CC(C)(C)C(=O)C1=CC2=C(C=C1)OCO2.CC(C)(C)CC1=CC(C(F)(F)F)=CC=C1.CC(C)(C)CC1=CC=C(OC(F)(F)F)C=C1.CC(C)(C)CCN1CCCCC1.CC(C)(C)CCN1CCOCC1.[C-]#[N+]C1=CC=C(CC(C)(C)C)C=C1 Chemical compound CC(C)(C)C(=O)C1=CC2=C(C=C1)OCO2.CC(C)(C)CC1=CC(C(F)(F)F)=CC=C1.CC(C)(C)CC1=CC=C(OC(F)(F)F)C=C1.CC(C)(C)CCN1CCCCC1.CC(C)(C)CCN1CCOCC1.[C-]#[N+]C1=CC=C(CC(C)(C)C)C=C1 CXBPKQWVXHXYQZ-UHFFFAOYSA-N 0.000 description 1\n\nMXFFNCXHLOJYLX-UHFFFAOYSA-N CC1CCN(C2=CC=C(NC(=O)C3=CC4=C(C=C3)OCO4)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC4=C(C=C3)OCO4)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC=C(OCCN4CCOCC4)C(F)=C3)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC(C)=CC=C1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC=C(C)C=C1 Chemical compound CC1CCN(C2=CC=C(NC(=O)C3=CC4=C(C=C3)OCO4)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC4=C(C=C3)OCO4)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC=C(OCCN4CCOCC4)C(F)=C3)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC(C)=CC=C1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC=C(C)C=C1 MXFFNCXHLOJYLX-UHFFFAOYSA-N 0.000 description 1\n\nHBNBAEQNYRCPGT-UHFFFAOYSA-N CC1CCN(C2=CC=C(NC(=O)C3=CC4=C(C=C3)OCO4)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC=C(OCCN4CCCCC4)C(F)=C3)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC=C(OCCN4CCOCC4)C(F)=C3)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC=C(C)C=C1.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C(N4CCN(C)CC4)C=C3)C=C2OC)C=C1 Chemical compound CC1CCN(C2=CC=C(NC(=O)C3=CC4=C(C=C3)OCO4)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC=C(OCCN4CCCCC4)C(F)=C3)C=C2)CC1.CN1CCN(C2=CC=C(NC(=O)C3=CC=C(OCCN4CCOCC4)C(F)=C3)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC=C(C)C=C1.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C(N4CCN(C)CC4)C=C3)C=C2OC)C=C1 HBNBAEQNYRCPGT-UHFFFAOYSA-N 0.000 description 1\n\nGGUXAQPRHYDBRJ-UHFFFAOYSA-N CCN(CC)CC.CN1CCN(C2=CC=C(N)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC(CO)=C1.COC1=CC(CO)=CC(C(C)=O)=C1 Chemical compound CCN(CC)CC.CN1CCN(C2=CC=C(N)C=C2)CC1.COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC(CO)=C1.COC1=CC(CO)=CC(C(C)=O)=C1 GGUXAQPRHYDBRJ-UHFFFAOYSA-N 0.000 description 1\n\nVVOFHVGYKXJLRL-UHFFFAOYSA-O CN1CCN(C(C)(C)C)CC1.COC1CCN(C(C)(C)C)CC1.COC1CC[NH+](C(C)(C)C)CC1.[Cl-] Chemical compound CN1CCN(C(C)(C)C)CC1.COC1CCN(C(C)(C)C)CC1.COC1CC[NH+](C(C)(C)C)CC1.[Cl-] VVOFHVGYKXJLRL-UHFFFAOYSA-O 0.000 description 1\n\nJZKHYHZPCRLKSF-UHFFFAOYSA-O COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC(C)=CC=C1.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C([NH+]4CCC(OC)CC4)C=C3)C=C2OC)C=C1.[Cl-] Chemical compound COC1=CC(C(=O)NC2=CC=C(N3CCN(C)CC3)C=C2)=CC=C1OCC1=CC(C)=CC=C1.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C([NH+]4CCC(OC)CC4)C=C3)C=C2OC)C=C1.[Cl-] JZKHYHZPCRLKSF-UHFFFAOYSA-O 0.000 description 1\n\nIUJGFHHTKSFFHE-UHFFFAOYSA-N COC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F Chemical compound COC=1C=C(C(=O)NC2=CC=C(C=C2)N2CCN(CC2)C)C=CC=1OCC1=CC=C(C=C1)OC(F)(F)F IUJGFHHTKSFFHE-UHFFFAOYSA-N 0.000 description 1\n\nDCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1\n\n206010058019 Cancer Pain Diseases 0.000 description 1\n\nWWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1\n\nOKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1\n\nWBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1\n\nYQJNMFAKSRRYBK-UHFFFAOYSA-N Cl.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C(N4CCC(OC)CC4)C=C3)C=C2OC)C=C1.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C(N4CCN(C)CC4)C=C3)C=C2OC)C=C1 Chemical compound Cl.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C(N4CCC(OC)CC4)C=C3)C=C2OC)C=C1.[C-]#[N+]C1=CC=C(COC2=CC=C(C(=O)NC3=CC=C(N4CCN(C)CC4)C=C3)C=C2OC)C=C1 YQJNMFAKSRRYBK-UHFFFAOYSA-N 0.000 description 1\n\n102000029816 Collagenase Human genes 0.000 description 1\n\n108060005980 Collagenase Proteins 0.000 description 1\n\n206010010144 Completed suicide Diseases 0.000 description 1\n\n206010010774 Constipation Diseases 0.000 description 1\n\nRGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1\n\n206010012335 Dependence Diseases 0.000 description 1\n\n239000004375 Dextrin Substances 0.000 description 1\n\n229920001353 Dextrin Polymers 0.000 description 1\n\nFEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1\n\n208000032131 Diabetic Neuropathies Diseases 0.000 description 1\n\n239000004338 Dichlorodifluoromethane Substances 0.000 description 1\n\n102100022188 Dihydropyrimidinase-related protein 1 Human genes 0.000 description 1\n\n102100024425 Dihydropyrimidinase-related protein 3 Human genes 0.000 description 1\n\n102100024443 Dihydropyrimidinase-related protein 4 Human genes 0.000 description 1\n\n102100024441 Dihydropyrimidinase-related protein 5 Human genes 0.000 description 1\n\nLVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1\n\n108090000790 Enzymes Proteins 0.000 description 1\n\n102000004190 Enzymes Human genes 0.000 description 1\n\nBDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1\n\nWHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1\n\n108010024636 Glutathione Proteins 0.000 description 1\n\n101000900531 Homo sapiens Dihydropyrimidinase-related protein 1 Proteins 0.000 description 1\n\n101001053501 Homo sapiens Dihydropyrimidinase-related protein 3 Proteins 0.000 description 1\n\n101001053490 Homo sapiens Dihydropyrimidinase-related protein 4 Proteins 0.000 description 1\n\n101001053479 Homo sapiens Dihydropyrimidinase-related protein 5 Proteins 0.000 description 1\n\nXQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1\n\n206010061218 Inflammation Diseases 0.000 description 1\n\n206010065390 Inflammatory pain Diseases 0.000 description 1\n\n206010050296 Intervertebral disc protrusion Diseases 0.000 description 1\n\nPIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1\n\nYQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1\n\nWHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1\n\n229920000881 Modified starch Polymers 0.000 description 1\n\nTXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\\C=C/C=C\\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1\n\n241000699666 Mus <mouse, genus> Species 0.000 description 1\n\nMBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1\n\n206010028813 Nausea Diseases 0.000 description 1\n\n108010025020 Nerve Growth Factor Proteins 0.000 description 1\n\n102000015336 Nerve Growth Factor Human genes 0.000 description 1\n\n206010029174 Nerve compression Diseases 0.000 description 1\n\n102000035092 Neutral proteases Human genes 0.000 description 1\n\n108091005507 Neutral proteases Proteins 0.000 description 1\n\n229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1\n\nGRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1\n\n208000001294 Nociceptive Pain Diseases 0.000 description 1\n\n102000007982 Phosphoproteins Human genes 0.000 description 1\n\n108010089430 Phosphoproteins Proteins 0.000 description 1\n\n206010036376 Postherpetic Neuralgia Diseases 0.000 description 1\n\n208000037674 Primary erythromelalgia Diseases 0.000 description 1\n\nIWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1\n\n208000004756 Respiratory Insufficiency Diseases 0.000 description 1\n\n206010038678 Respiratory depression Diseases 0.000 description 1\n\n206010039897 Sedation Diseases 0.000 description 1\n\n102000013008 Semaphorin-3A Human genes 0.000 description 1\n\n108010090319 Semaphorin-3A Proteins 0.000 description 1\n\n208000010261 Small Fiber Neuropathy Diseases 0.000 description 1\n\n206010073928 Small fibre neuropathy Diseases 0.000 description 1\n\n108010052164 Sodium Channels Proteins 0.000 description 1\n\n102000018674 Sodium Channels Human genes 0.000 description 1\n\n235000021355 Stearic acid Nutrition 0.000 description 1\n\n208000006011 Stroke Diseases 0.000 description 1\n\n238000000692 Student's t-test Methods 0.000 description 1\n\nKDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1\n\nNINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1\n\nFEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1\n\nGSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1\n\nFVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1\n\n108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1\n\n238000002835 absorbance Methods 0.000 description 1\n\n125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1\n\n239000002253 acid Substances 0.000 description 1\n\n230000002378 acidificating effect Effects 0.000 description 1\n\n239000012190 activator Substances 0.000 description 1\n\n239000013543 active substance Substances 0.000 description 1\n\n125000002252 acyl group Chemical group 0.000 description 1\n\n239000000853 adhesive Substances 0.000 description 1\n\n238000013019 agitation Methods 0.000 description 1\n\n229910001413 alkali metal ion Inorganic materials 0.000 description 1\n\n125000003282 alkyl amino group Chemical group 0.000 description 1\n\n206010053552 allodynia Diseases 0.000 description 1\n\nBJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1\n\n229910052782 aluminium Inorganic materials 0.000 description 1\n\n229910000147 aluminium phosphate Inorganic materials 0.000 description 1\n\n125000003277 amino group Chemical group 0.000 description 1\n\n230000000202 analgesic effect Effects 0.000 description 1\n\n239000012491 analyte Substances 0.000 description 1\n\n235000019558 anosmia Nutrition 0.000 description 1\n\n239000008135 aqueous vehicle Substances 0.000 description 1\n\n150000001491 aromatic compounds Chemical class 0.000 description 1\n\n125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1\n\n230000002917 arthritic effect Effects 0.000 description 1\n\n235000021311 artificial sweeteners Nutrition 0.000 description 1\n\n125000004429 atom Chemical group 0.000 description 1\n\nSRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1\n\n229940092714 benzenesulfonic acid Drugs 0.000 description 1\n\n235000010233 benzoic acid Nutrition 0.000 description 1\n\n125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1\n\nGONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1\n\n125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1\n\n125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1\n\n239000011230 binding agent Substances 0.000 description 1\n\n229920002988 biodegradable polymer Polymers 0.000 description 1\n\n239000004621 biodegradable polymer Substances 0.000 description 1\n\n230000004071 biological effect Effects 0.000 description 1\n\n210000000988 bone and bone Anatomy 0.000 description 1\n\n239000005388 borosilicate glass Substances 0.000 description 1\n\n125000001246 bromo group Chemical group Br* 0.000 description 1\n\n239000000872 buffer Substances 0.000 description 1\n\nKDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1\n\n230000009460 calcium influx Effects 0.000 description 1\n\n239000001506 calcium phosphate Substances 0.000 description 1\n\n229910000389 calcium phosphate Inorganic materials 0.000 description 1\n\n235000011010 calcium phosphates Nutrition 0.000 description 1\n\n230000003185 calcium uptake Effects 0.000 description 1\n\n150000004657 carbamic acid derivatives Chemical class 0.000 description 1\n\n229910052799 carbon Inorganic materials 0.000 description 1\n\n239000001569 carbon dioxide Substances 0.000 description 1\n\n229960004424 carbon dioxide Drugs 0.000 description 1\n\n238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1\n\n150000003943 catecholamines Chemical class 0.000 description 1\n\n238000004113 cell culture Methods 0.000 description 1\n\n230000030833 cell death Effects 0.000 description 1\n\n230000033077 cellular process Effects 0.000 description 1\n\n239000013522 chelant Substances 0.000 description 1\n\n238000002512 chemotherapy Methods 0.000 description 1\n\n125000001309 chloro group Chemical group Cl* 0.000 description 1\n\nKYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1\n\n230000001684 chronic effect Effects 0.000 description 1\n\n235000013985 cinnamic acid Nutrition 0.000 description 1\n\n229930016911 cinnamic acid Natural products 0.000 description 1\n\n210000003703 cisterna magna Anatomy 0.000 description 1\n\n235000015165 citric acid Nutrition 0.000 description 1\n\n230000006395 clathrin-mediated endocytosis Effects 0.000 description 1\n\n229960002424 collagenase Drugs 0.000 description 1\n\n238000004440 column chromatography Methods 0.000 description 1\n\n239000000306 component Substances 0.000 description 1\n\n230000001143 conditioned effect Effects 0.000 description 1\n\n230000001268 conjugating effect Effects 0.000 description 1\n\n238000013270 controlled release Methods 0.000 description 1\n\n239000013078 crystal Substances 0.000 description 1\n\n238000005520 cutting process Methods 0.000 description 1\n\n125000004093 cyano group Chemical group *C#N 0.000 description 1\n\n125000000000 cycloalkoxy group Chemical group 0.000 description 1\n\n125000000753 cycloalkyl group Chemical group 0.000 description 1\n\n125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1\n\n230000006378 damage Effects 0.000 description 1\n\n230000034994 death Effects 0.000 description 1\n\n230000002939 deleterious effect Effects 0.000 description 1\n\n235000019425 dextrin Nutrition 0.000 description 1\n\nPXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1\n\n235000019404 dichlorodifluoromethane Nutrition 0.000 description 1\n\n229940042935 dichlorodifluoromethane Drugs 0.000 description 1\n\n229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1\n\n235000014113 dietary fatty acids Nutrition 0.000 description 1\n\nZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1\n\n238000002224 dissection Methods 0.000 description 1\n\nMOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1\n\n238000012377 drug delivery Methods 0.000 description 1\n\n230000007831 electrophysiology Effects 0.000 description 1\n\n238000002001 electrophysiology Methods 0.000 description 1\n\n238000004520 electroporation Methods 0.000 description 1\n\n230000001804 emulsifying effect Effects 0.000 description 1\n\n238000005516 engineering process Methods 0.000 description 1\n\n239000002702 enteric coating Substances 0.000 description 1\n\n238000009505 enteric coating Methods 0.000 description 1\n\n229940088598 enzyme Drugs 0.000 description 1\n\n210000002615 epidermis Anatomy 0.000 description 1\n\n230000001667 episodic effect Effects 0.000 description 1\n\n150000002148 esters Chemical class 0.000 description 1\n\nAFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1\n\nCCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1\n\n125000001033 ether group Chemical group 0.000 description 1\n\n125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1\n\nLVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1\n\n229940093471 ethyl oleate Drugs 0.000 description 1\n\n229960004979 fampridine Drugs 0.000 description 1\n\n239000000194 fatty acid Substances 0.000 description 1\n\n229930195729 fatty acid Natural products 0.000 description 1\n\n239000000835 fiber Substances 0.000 description 1\n\n239000000706 filtrate Substances 0.000 description 1\n\n238000003818 flash chromatography Methods 0.000 description 1\n\n239000006260 foam Substances 0.000 description 1\n\n235000013355 food flavoring agent Nutrition 0.000 description 1\n\n150000004675 formic acid derivatives Chemical class 0.000 description 1\n\n125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1\n\n238000004108 freeze drying Methods 0.000 description 1\n\n239000001530 fumaric acid Substances 0.000 description 1\n\n235000011087 fumaric acid Nutrition 0.000 description 1\n\n125000000524 functional group Chemical group 0.000 description 1\n\n229960002870 gabapentin Drugs 0.000 description 1\n\n210000000609 ganglia Anatomy 0.000 description 1\n\n239000007789 gas Substances 0.000 description 1\n\n239000003349 gelling agent Substances 0.000 description 1\n\n239000011521 glass Substances 0.000 description 1\n\n239000000174 gluconic acid Chemical group 0.000 description 1\n\n235000012208 gluconic acid Nutrition 0.000 description 1\n\n239000008103 glucose Substances 0.000 description 1\n\n239000004220 glutamic acid Chemical group 0.000 description 1\n\n235000013922 glutamic acid Nutrition 0.000 description 1\n\n229960003180 glutathione Drugs 0.000 description 1\n\n235000011187 glycerol Nutrition 0.000 description 1\n\n239000008187 granular material Substances 0.000 description 1\n\n150000004820 halides Chemical class 0.000 description 1\n\n229910052736 halogen Inorganic materials 0.000 description 1\n\n150000002367 halogens Chemical class 0.000 description 1\n\n210000003128 head Anatomy 0.000 description 1\n\n238000012203 high throughput assay Methods 0.000 description 1\n\n210000000548 hind-foot Anatomy 0.000 description 1\n\n239000008240 homogeneous mixture Substances 0.000 description 1\n\n230000002209 hydrophobic effect Effects 0.000 description 1\n\n125000004356 hydroxy functional group Chemical group O* 0.000 description 1\n\nNPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1\n\n239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1\n\n235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1\n\n229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1\n\nUFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1\n\n230000037417 hyperactivation Effects 0.000 description 1\n\n230000002102 hyperpolarization Effects 0.000 description 1\n\n239000007943 implant Substances 0.000 description 1\n\n238000002513 implantation Methods 0.000 description 1\n\n238000000099 in vitro assay Methods 0.000 description 1\n\n230000006698 induction Effects 0.000 description 1\n\n230000002757 inflammatory effect Effects 0.000 description 1\n\n230000004054 inflammatory process Effects 0.000 description 1\n\n230000004941 influx Effects 0.000 description 1\n\n230000000977 initiatory effect Effects 0.000 description 1\n\n230000003993 interaction Effects 0.000 description 1\n\n238000001361 intraarterial administration Methods 0.000 description 1\n\n230000006525 intracellular process Effects 0.000 description 1\n\n238000007918 intramuscular administration Methods 0.000 description 1\n\n238000001990 intravenous administration Methods 0.000 description 1\n\n125000002346 iodo group Chemical group I* 0.000 description 1\n\n150000002500 ions Chemical class 0.000 description 1\n\n229960002725 isoflurane Drugs 0.000 description 1\n\n238000002955 isolation Methods 0.000 description 1\n\n125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1\n\n229960003299 ketamine Drugs 0.000 description 1\n\n210000003734 kidney Anatomy 0.000 description 1\n\n238000011813 knockout mouse model Methods 0.000 description 1\n\n239000004310 lactic acid Substances 0.000 description 1\n\n235000014655 lactic acid Nutrition 0.000 description 1\n\n230000000670 limiting effect Effects 0.000 description 1\n\n150000002632 lipids Chemical class 0.000 description 1\n\n230000004777 loss-of-function mutation Effects 0.000 description 1\n\n239000000314 lubricant Substances 0.000 description 1\n\n210000004705 lumbosacral region Anatomy 0.000 description 1\n\n239000011777 magnesium Substances 0.000 description 1\n\nZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1\n\n239000001095 magnesium carbonate Substances 0.000 description 1\n\n229910000021 magnesium carbonate Inorganic materials 0.000 description 1\n\n235000019359 magnesium stearate Nutrition 0.000 description 1\n\n229910052943 magnesium sulfate Inorganic materials 0.000 description 1\n\n238000012423 maintenance Methods 0.000 description 1\n\nVZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1\n\n239000011976 maleic acid Substances 0.000 description 1\n\n239000001630 malic acid Substances 0.000 description 1\n\n235000011090 malic acid Nutrition 0.000 description 1\n\n238000007726 management method Methods 0.000 description 1\n\n229960002510 mandelic acid Drugs 0.000 description 1\n\n238000001819 mass spectrum Methods 0.000 description 1\n\n238000002483 medication Methods 0.000 description 1\n\n239000012528 membrane Substances 0.000 description 1\n\n230000003340 mental effect Effects 0.000 description 1\n\n229910021645 metal ion Inorganic materials 0.000 description 1\n\n229940098779 methanesulfonic acid Drugs 0.000 description 1\n\n125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1\n\nWBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1\n\n150000007522 mineralic acids Chemical class 0.000 description 1\n\n238000002156 mixing Methods 0.000 description 1\n\n235000019426 modified starch Nutrition 0.000 description 1\n\n229960005181 morphine Drugs 0.000 description 1\n\n125000002757 morpholinyl group Chemical group 0.000 description 1\n\n239000002324 mouth wash Substances 0.000 description 1\n\n201000006417 multiple sclerosis Diseases 0.000 description 1\n\nCGDLWHGPJPVPDU-ATVHPVEESA-N n-[(5z)-5-[(4-bromophenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]naphthalene-1-sulfonamide Chemical compound C1=CC(Br)=CC=C1\\C=C/1C(=O)N=C(NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)S\\1 CGDLWHGPJPVPDU-ATVHPVEESA-N 0.000 description 1\n\nSYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1\n\n125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1\n\nKVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1\n\n125000001624 naphthyl group Chemical group 0.000 description 1\n\n230000003533 narcotic effect Effects 0.000 description 1\n\n235000021096 natural sweeteners Nutrition 0.000 description 1\n\n230000008693 nausea Effects 0.000 description 1\n\n210000005036 nerve Anatomy 0.000 description 1\n\n229940053128 nerve growth factor Drugs 0.000 description 1\n\nQMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1\n\n229910017604 nitric acid Inorganic materials 0.000 description 1\n\nQJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1\n\n231100000252 nontoxic Toxicity 0.000 description 1\n\n230000003000 nontoxic effect Effects 0.000 description 1\n\n230000001473 noxious effect Effects 0.000 description 1\n\nQIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1\n\nOQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1\n\n235000008390 olive oil Nutrition 0.000 description 1\n\n239000004006 olive oil Substances 0.000 description 1\n\n238000001543 one-way ANOVA Methods 0.000 description 1\n\n238000005457 optimization Methods 0.000 description 1\n\n150000007524 organic acids Chemical class 0.000 description 1\n\n235000005985 organic acids Nutrition 0.000 description 1\n\n150000007530 organic bases Chemical class 0.000 description 1\n\n150000002895 organic esters Chemical class 0.000 description 1\n\n239000003960 organic solvent Substances 0.000 description 1\n\n230000008058 pain sensation Effects 0.000 description 1\n\n229940124707 pain therapeutics Drugs 0.000 description 1\n\nFJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1\n\n238000007911 parenteral administration Methods 0.000 description 1\n\n239000006072 paste Substances 0.000 description 1\n\n235000010603 pastilles Nutrition 0.000 description 1\n\n239000001814 pectin Substances 0.000 description 1\n\n235000010987 pectin Nutrition 0.000 description 1\n\n229920001277 pectin Polymers 0.000 description 1\n\n239000003961 penetration enhancing agent Substances 0.000 description 1\n\n125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1\n\n210000001428 peripheral nervous system Anatomy 0.000 description 1\n\n208000033808 peripheral neuropathy Diseases 0.000 description 1\n\n239000000825 pharmaceutical preparation Substances 0.000 description 1\n\n230000000144 pharmacologic effect Effects 0.000 description 1\n\nUYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1\n\nRGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1\n\n239000003504 photosensitizing agent Substances 0.000 description 1\n\nIEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1\n\n125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1\n\n125000003386 piperidinyl group Chemical group 0.000 description 1\n\nIUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1\n\n229920000747 poly(lactic acid) Polymers 0.000 description 1\n\n239000004626 polylactic acid Substances 0.000 description 1\n\n230000004481 post-translational protein modification Effects 0.000 description 1\n\nWSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1\n\n238000001556 precipitation Methods 0.000 description 1\n\n230000002335 preservative effect Effects 0.000 description 1\n\n239000003380 propellant Substances 0.000 description 1\n\n235000019260 propionic acid Nutrition 0.000 description 1\n\n230000006916 protein interaction Effects 0.000 description 1\n\nYQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1\n\n238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1\n\n230000005180 public health Effects 0.000 description 1\n\n230000002685 pulmonary effect Effects 0.000 description 1\n\nUMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1\n\n125000000719 pyrrolidinyl group Chemical group 0.000 description 1\n\n229940107700 pyruvic acid Drugs 0.000 description 1\n\n238000011002 quantification Methods 0.000 description 1\n\n125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1\n\nIUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1\n\n125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1\n\n125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1\n\n230000009257 reactivity Effects 0.000 description 1\n\n238000011084 recovery Methods 0.000 description 1\n\n230000009467 reduction Effects 0.000 description 1\n\n238000011160 research Methods 0.000 description 1\n\n239000011347 resin Substances 0.000 description 1\n\n229920005989 resin Polymers 0.000 description 1\n\n210000002345 respiratory system Anatomy 0.000 description 1\n\n229960004889 salicylic acid Drugs 0.000 description 1\n\n238000007423 screening assay Methods 0.000 description 1\n\n230000036280 sedation Effects 0.000 description 1\n\n210000002966 serum Anatomy 0.000 description 1\n\n239000000741 silica gel Substances 0.000 description 1\n\n229910002027 silica gel Inorganic materials 0.000 description 1\n\n229920002379 silicone rubber Polymers 0.000 description 1\n\n239000004945 silicone rubber Substances 0.000 description 1\n\n238000009097 single-agent therapy Methods 0.000 description 1\n\n150000003384 small molecules Chemical class 0.000 description 1\n\n229910000030 sodium bicarbonate Inorganic materials 0.000 description 1\n\n239000012453 solvate Substances 0.000 description 1\n\n239000001593 sorbitan monooleate Substances 0.000 description 1\n\n235000011069 sorbitan monooleate Nutrition 0.000 description 1\n\n229940035049 sorbitan monooleate Drugs 0.000 description 1\n\n238000001228 spectrum Methods 0.000 description 1\n\n210000000278 spinal cord Anatomy 0.000 description 1\n\n238000012453 sprague-dawley rat model Methods 0.000 description 1\n\n230000000087 stabilizing effect Effects 0.000 description 1\n\n239000007858 starting material Substances 0.000 description 1\n\n239000008117 stearic acid Chemical group 0.000 description 1\n\n125000003107 substituted aryl group Chemical group 0.000 description 1\n\n239000011593 sulfur Substances 0.000 description 1\n\n239000004094 surface-active agent Substances 0.000 description 1\n\n238000001356 surgical procedure Methods 0.000 description 1\n\n230000002459 sustained effect Effects 0.000 description 1\n\n210000000331 sympathetic ganglia Anatomy 0.000 description 1\n\n208000011580 syndromic disease Diseases 0.000 description 1\n\n239000006188 syrup Substances 0.000 description 1\n\n235000020357 syrup Nutrition 0.000 description 1\n\n239000000454 talc Substances 0.000 description 1\n\n229910052623 talc Inorganic materials 0.000 description 1\n\n230000008685 targeting Effects 0.000 description 1\n\n239000011975 tartaric acid Substances 0.000 description 1\n\n235000002906 tartaric acid Nutrition 0.000 description 1\n\n125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1\n\n125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1\n\n230000008719 thickening Effects 0.000 description 1\n\n210000001519 tissue Anatomy 0.000 description 1\n\nJOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1\n\n230000000699 topical effect Effects 0.000 description 1\n\n230000037317 transdermal delivery Effects 0.000 description 1\n\n239000012096 transfection reagent Substances 0.000 description 1\n\n230000009466 transformation Effects 0.000 description 1\n\n230000032258 transport Effects 0.000 description 1\n\n238000011269 treatment regimen Methods 0.000 description 1\n\nQORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1\n\nCYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1\n\n229940029284 trichlorofluoromethane Drugs 0.000 description 1\n\n125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1\n\n210000000427 trigeminal ganglion Anatomy 0.000 description 1\n\n125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1\n\nLENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1\n\n229960000281 trometamol Drugs 0.000 description 1\n\n210000000689 upper leg Anatomy 0.000 description 1\n\nWKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1\n\nTUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1\n\n235000015112 vegetable and seed oil Nutrition 0.000 description 1\n\n239000008158 vegetable oil Substances 0.000 description 1\n\nFVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1\n\n239000011345 viscous material Substances 0.000 description 1\n\n102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1\n\n108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1\n\n238000009736 wetting Methods 0.000 description 1\n\n229960001600 xylazine Drugs 0.000 description 1\n\nBPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1\n\nImages\n\nClassifications\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K31/00—Medicinal preparations containing organic active ingredients\n\nA61K31/33—Heterocyclic compounds\n\nA61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins\n\nA61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines\n\nA61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K31/00—Medicinal preparations containing organic active ingredients\n\nA61K31/33—Heterocyclic compounds\n\nA61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins\n\nA61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom\n\nA61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof\n\nA61K31/445—Non condensed piperidines, e.g. piperocaine\n\nA61K31/452—Piperidinium derivatives\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K31/00—Medicinal preparations containing organic active ingredients\n\nA61K31/33—Heterocyclic compounds\n\nA61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins\n\nA61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom\n\nA61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof\n\nA61K31/445—Non condensed piperidines, e.g. piperocaine\n\nA61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems\n\nA61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K31/00—Medicinal preparations containing organic active ingredients\n\nA61K31/33—Heterocyclic compounds\n\nA61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins\n\nA61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K31/00—Medicinal preparations containing organic active ingredients\n\nA61K31/33—Heterocyclic compounds\n\nA61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins\n\nA61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines\n\nA61K31/5375—1,4-Oxazines, e.g. morpholine\n\nA61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P25/00—Drugs for disorders of the nervous system\n\nA61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies\n\nC—CHEMISTRY; METALLURGY\n\nC07—ORGANIC CHEMISTRY\n\nC07D—HETEROCYCLIC COMPOUNDS\n\nC07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms\n\nC07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms\n\nC07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms\n\nC07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings\n\nC—CHEMISTRY; METALLURGY\n\nC07—ORGANIC CHEMISTRY\n\nC07D—HETEROCYCLIC COMPOUNDS\n\nC07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms\n\nC07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms\n\nC07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof\n\nC07D295/182—Radicals derived from carboxylic acids\n\nC07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids\n\nC—CHEMISTRY; METALLURGY\n\nC07—ORGANIC CHEMISTRY\n\nC07D—HETEROCYCLIC COMPOUNDS\n\nC07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms\n\nC07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3\n\nC07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems\n\nC07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring\n\nC07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring\n\nC07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring\n\nC07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen\n\nC—CHEMISTRY; METALLURGY\n\nC07—ORGANIC CHEMISTRY\n\nC07D—HETEROCYCLIC COMPOUNDS\n\nC07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom\n\nC07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings\n\nC07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links\n\nDefinitions\n\nthe present invention relates to compounds that can modulate the amount of voltage-gated sodium channel Nav1.7 protein that is present on neuronal surface and methods for using such compounds.\n\ncompounds of the invention modulate the amount of Nav1.7 protein on the cellular surface by inhibiting SUMOylation of CRMP2, where SUMOylation is the addition of small ubiquitin-like modifier (SUMO).\n\nSUMO small ubiquitin-like modifier\n\nChronic pain and in particular neuropathic pain, affects millions of individuals, costs billions of dollars, and is a major cause of morbidity, suffering, and suicide. Although some chronic pain conditions can be treated adequately with existing drugs, a large number of patients fail to achieve adequate pain relief, even with polypharmacy. Furthermore, currently available opioid pain therapies, which are generally only partially effective, are often associated with many side effects that limit their clinical efficacy, including tolerance and addiction.\n\nSome aspects of the invention are directed to SUMOylation inhibitors of CRMP2. It is believed that inhibiting SUMOylation of CRMP2 results in reduction in the number of Nav1.7 proteins on the cellular surface, thereby alleviating various clinical conditions associated with the excessive presence and/or hyper-activation of cellular surface Nav1.7.\n\nSUMOylation inhibitors of CRMP2 is a compound is of the formula: Ar a1 -L a1 -Ar a2 âR a1 (Compound I); where Ar a1 is optionally substituted phenyl; L a1 is a linker having a hydrogen bond acceptor moiety; Ar a2 is phenylene, pyridylene or pyrazinylene, each of which is optionally substituted; R a1 is heterocyclyl or heteroalkyl having at least one hydrogen bond acceptor; Ar b1 is benzo[d][1,3]dioxolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[d]imidazolyl, naphthyl or quinolinyl; L b1 is a conformationally constrained linker; R b1 is heterocyclyl or nitrogen-heteroalkyl; Ar c1 is 2,3-di\n\nAr a1 and R a1 are those defined herein.\n\nFIG. 1 is a bar graph showing ability of representative compounds of the invention to attenuate veratradine-induced increase in cytosolic Na + in rat dorsal root ganglion (DRG) neurons in culture.\n\nDRG root ganglion\n\nFIGS. 2-4 show experimental results in graphic forms showing compounds of the invention inhibiting tetrodotoxin sensitive (TTX-S) NaV1.7 currents in rat DRGs.\n\npanels A are graphic summary of activation\n\npanels B are graphic summary of inactivation fits\n\npanels C are graphs of current-voltage relationship\n\npanels D show use-dependent inactivation from rat DRGs treated with DMSO or the compounds of the invention.\n\nFIG. 5 is experimental results of a compound of the invention inhibiting TTX-S NaV1.7 currents in rat and human DRGs.\n\nPanel A shows representative family of sodium current traces.\n\nPanel B shows summary peak currents of compound AZ002.\n\nPanel C shows activation and inactivation fits from rat DRGs treated with DMSO or a compound of the invention.\n\nPanel D is a photograph showing two human DRGs (yellow arrows) in a mixed glia-DRG co-culture demonstrating that overnight incubation with AZ002 does not affect cell morphology or health.\n\nPanel E shows family of current traces demonstrating inhibition of H-infinity subtracted (i.e., NaV1.7) currents in human DRGs treated with AZ002.\n\nAlkyl refers to a saturated linear monovalent hydrocarbon moiety of one to twelve, typically one to six, carbon atoms or a saturated branched monovalent hydrocarbon moiety of three to twelve, preferably three to six, carbon atoms.\n\nExemplary alkyl group include, but are not limited to, methyl, ethyl, n-propyl, 2-propyl, tert-butyl, pentyl, and the like.\n\nAlkylene refers to a saturated linear divalent hydrocarbon moiety of one to twelve, typically one to six, carbon atoms or a branched saturated divalent hydrocarbon moiety of three to twelve, preferably three to six, carbon atoms.\n\nExemplary alkylene groups include, but are not limited to, methylene, ethylene, propylene, butylene, pentylene, and the like.\n\nAryl refers to a monovalent mono-, bi- or tricyclic aromatic hydrocarbon moiety of 6 to 15 ring atoms which is optionally substituted with one or more, preferably one, two, or three substituents within the ring structure. When two or more substituents are present in an aryl group, each substituent is independently selected.\n\nHaloalkyl refers to an alkyl group as defined herein in which one or more hydrogen atom is replaced by same or different halo atoms.\n\nhaloalkyl also includes perhalogenated alkyl groups in which all alkyl hydrogen atoms are replaced by halogen atoms.\n\nExemplary haloalkyl groups include, but are not limited to, âCH 2 Cl, âCF 3 , âCH 2 CF 3 , âCH 2 CCl 3 , and the like.\n\nHeterocyclyl means a non-aromatic monocyclic moiety of three to eight ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O) n (where n is an integer from 0 to 2), the remaining ring atoms being C, where one or two C atoms can optionally be a carbonyl group.\n\nthe heterocyclyl ring can be optionally substituted independently with one or more, preferably one, two, or three, substituents. When two or more substituents are present in a heterocyclyl group, each substituent is independently selected.\n\nâPharmaceutically acceptable excipientâ refers to an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use.\n\nâPharmaceutically acceptable saltâ of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.\n\nSuch salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, cam\n\nprodrug and âprodrugâ are used interchangeably herein and refer to any compound which releases an active parent drug according to Formula I in vivo when such prodrug is administered to a mammalian subject.\n\nProdrugs of a compound of Formula I are prepared by modifying one or more functional group(s) present in the compound of Formula I in such a way that the modification(s) may be cleaved in vivo to release the parent compound.\n\nProdrugs include compounds of Formula I wherein a hydroxy, amino, or sulfhydryl group in a compound of Formula I is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively.\n\nprodrugs include, but are not limited to, esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds of Formula I, and the like.\n\nProtecting group refers to a moiety, except alkyl groups, that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T. W. Greene and P. G. M.\n\nhydroxy protecting groups include acyl groups, benzyl and trityl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.\n\nRepresentative amino protecting groups include, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), and the like.\n\nâCorresponding protecting groupâ means an appropriate protecting group corresponding to the heteroatom (i.e., N, O, P or S) to which it is attached.\n\na therapeutically effective amount means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease.\n\nthe âtherapeutically effective amountâ will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.\n\nTreatingâ or âtreatmentâ of a disease includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.\n\nthe terms âtreatingâ, âcontactingâ and âreactingâ are used interchangeably herein, and refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product.\n\nreaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.\n\nthe terms âthose defined aboveâ and âthose defined hereinâ when referring to a variable incorporates by reference the broad definition of the variable as well as any narrow and/or preferred, more preferred and most preferred definitions, if any.\n\ncompounds of the invention can be used to treat any number of clinical conditions that is associated with the presence of Nav1.7 on cellular surface.\n\ncompounds of the invention are used to treat pain including chronic and/or acute pain.\n\nthe voltage-gated Nav1.7 sodium channel is preferentially expressed in the peripheral nervous system within ganglia related to nociceptive pain, including dorsal root ganglia (DRG), trigeminal ganglia and sympathetic ganglia.\n\nDRG dorsal root ganglia\n\nthe channel modulates voltage activation threshold required to fire action potentials in response to stimuli.\n\nGain-of-function mutations i.e., those that lower Nav1.7 current threshold for initiation of action potentials, produce allodyniaâa lowered stimulus threshold for pain. Such mutations are the cause of pain syndromes including erythromelalgia, paroxysmal extreme pain disorder, and small fiber neuropathy.\n\nNav1.7 Increased presence of Nav1.7 on cellular surface has also been associated with pain resulting from diabetic neuropathy, inflammation, following combined sciatic nerve compression, nucleus pulposus application modeling lumbar disc herniation, and after spared nerve injury (SNI).\n\nSNI spared nerve injury\n\nloss-of-function mutations in Nav1.7 prevent stimuli from reaching threshold to propagate pain. Patients with such mutations display a complete loss of pain sensation.\n\nhyperalgesia i.e., an increased response to a painful stimulus\n\ncomplete Freund's adjuvant complete Freund's adjuvant\n\ncompounds of the invention modulate the amount of Nav1.7 protein that is present on cell surface and therefore the cellular excitability controlled by this protein.\n\ncompounds of the invention modulate (e.g., inhibit) an intracellular process that is responsible for effectuating the cellular trafficking of a particular voltage gated sodium channel to the cellular surface, thereby selectively reducing the presence of this channel (i.e., Nav1.7 protein) on the cell surface.\n\nSUMOylation is a post-translational modification involved in various cellular processes.\n\nthe term âSUMOâ refers to Small Ubiquitin-like Modifier.\n\nSUMO proteins are a family of small proteins that covalently attach to and detach from target proteins in cells to modify their function.\n\nmodulating or inhibiting âSUMOylationâ or âSUMOylation processâ means modulating or inhibiting attachment of SUMO proteins and/or modulating or inhibiting modification of a protein after attachment of SUMO proteins.\n\nCRMP2 is a member of the collapsin response mediator protein (CRMP) family that consists of five intracellular phosphoproteins (CRMP1, CRMP2, CRMP3, CRMP4, CRMP5) of similar molecular size (60-66 kDa). It has been found that compounds that can modulate expression or biological activity of CRMP2 also can be used to treat clinical conditions associated with neurological diseases such as Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, and stroke. Accordingly, in some embodiments, compounds of the invention can be used to treat neurological diseases such as Alzheimer's disease, Parkinson's disease, and/or stroke including the pain associated with some of these diseases.\n\nCRMP collapsin response mediator protein\n\ncompounds of the invention can be used to treat various types of pain including chronic pain and acute pain, and itch as well as anosmia.\n\nexemplary chronic pains that can be treated with compounds of the invention include, but are not limited to, cancer pain, burn pain, arthritic pain, chemotherapy-induced peripheral neuropathy, post-herpetic neuralgia, episodic pain such as primary erythromelalgia and paroxysmal extreme pain disorder, etc.\n\nexemplary acute pains that can be treated by compounds of the invention include, but are not limited to, noxious heat pain, itch, and surgical pain.\n\nsome of the advantages of compounds of the invention include, but are not limited to, no motor impairment or sedation, higher potency and equivalent efficacy to morphine and gabapentin at a given dose level, and non-existent or vastly reduced potential for rewarding effect and potential for abuse compared to narcotic analgesics.\n\naspects of the invention include methods for treating pain in a subject, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the invention.\n\nAnother aspect of the invention include a method for treating a clinical condition associated with the presence and/or activation of Nav1.7 protein on cellular surface, said method comprising administering a therapeutically effective amount of a compound of the invention to a subject suffering from a clinical condition associated with the presence and/or activation of Nav1.7 protein on the cellular surface thereby reducing the amount of Nav1.7 protein on the cellular surface.\n\ncompounds of the invention reduce the amount of Nav1.7 present on the neuronal cellular surface by inhibiting SUMOylation of CRMP2.\n\nSome of the representative compounds of the invention include, but are not limited to, compounds of the formula: Ar a1 -L a1 -Ar a2 âR a1 (Compound I);\n\nAr a1 is optionally substituted aryl such as phenyl or pyridine.\n\nAr a1 is substituted phenyl with a substituent on the 3-, 4-and/or the 5-position (relative to the carbon having L a1 , which is arbitrarily designated as the C1 â position).\n\nExemplary substituents for phenyl group (e.g., Ar a1 and Ar a2 ) in Compound of Formula I (or any other phenyl group in compounds of the invention) include alkoxy (e.g., methoxy, isopropyloxy, etc.), cycloalkoxy (e.g., cyclopropyloxy), aryloxy, (e.g., phenoxy, where phenyl group of phenoxy is optionally substituted as described herein), alkyl, haloalkyl, haloalkoxy (i.e., RâOâ, where R is haloalkyl, such as trifluoromethoxy etc.), fluoro, cyano, aralkoxy (i.e., ArâRâ"
    }
}